MyFinsight
Home
Blog
About
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. (COAG)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$187,506K
Free Cash flow
-$22,660K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Maturities of available-for-sale...
Equity-based compensation
Others
Negative Cash Flow Breakdown
Purchases of available-for-sale ...
Net loss
Accretion of discount on availab...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-24,150
-22,687
Equity-based compensation
2,015
1,318
Depreciation and amortization
75
73
Non-cash lease expense
-160
-153
Accretion of discount on available-for-sale debt securities
1,319
816
Prepaid expenses and other current assets
638
-1,166
Other non-current assets
739
1,016
Accounts payable
550
-52
Accrued expenses and other current liabilities
1,568
434
Operating lease liabilities
-159
-157
Net cash used in operating activities
-22,637
-21,584
Purchases of available-for-sale debt securities
132,473
15,735
Maturities of available-for-sale debt securities
25,059
-
Purchases of property and equipment
23
112
Net cash (used in) provided by investing activities
-107,437
-15,847
Payment of offering costs
-
414
Proceeds from issuance of common stock, net of issuance costs of 29.6 million
317,165
-
Principal payments on finance lease
0
46
Net cash provided by (used in) financing activities
317,579
-460
Effect of foreign exchange rate changes on cash and cash equivalents
1
-223
Net increase (decrease) in cash and cash equivalents
187,506
-38,114
Cash and cash equivalents at beginning of period
49,860
87,974
Cash and cash equivalents at end of period
237,366
49,860
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$317,165K
Net cash provided by
(used in) financing...
$317,579K
Effect of foreign
exchange rate changes on...
$1K
Net increase
(decrease) in cash and cash...
$187,506K
Canceled cashflow
$130,074K
Maturities of
available-for-sale debt securities
$25,059K
Equity-based compensation
$2,015K
Accrued expenses and
other current...
$1,568K
Accounts payable
$550K
Non-cash lease expense
-$160K
Depreciation and
amortization
$75K
Net cash (used in)
provided by investing...
-$107,437K
Net cash used in
operating activities
-$22,637K
Canceled cashflow
$25,059K
Canceled cashflow
$4,368K
Purchases of
available-for-sale debt securities
$132,473K
Net loss
-$24,150K
Purchases of property and
equipment
$23K
Accretion of discount on
available-for-sale debt securities
$1,319K
Other non-current
assets
$739K
Prepaid expenses and
other current assets
$638K
Operating lease
liabilities
-$159K
Buy us a coffee